The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment

CNS Neuroscience and Therapeutics

Volumn 20, Issue 2, 2014, Pages 125-130

  Lin, Yong Juan ^a,b   Li, Jing Wei ^a,b   Zhang, Mei Juan ^a,b   Qian, Lai ^a,b   Yang, Wen Jie ^a,b   Zhang, Chun Lei ^c   Shao, Yuan ^a,b   Zhang, Yang ^a,b   Huang, Yu Jie ^b   Xu, Yun ^a,b  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b Jiangsu Province Stroke Center for Diagnosis and Therapy   (China)

^c Nanjing Sichuang Biotechnology Co Ltd   (China)

Author keywords

In stent restenosis; Risk factors; Stroke; Vertebral artery

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

AGED; ALLELE; ARTERIAL STENT; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CYP2C19 GENE; CYP3A4 GENE; DIGITAL SUBTRACTION ANGIOGRAPHY; FEMALE; FUNCTION TEST; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HYPERLIPIDEMIA; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; P2Y12 GENE; RISK FACTOR; STROKE PATIENT; ULTRASOUND; VERTEBRAL ARTERY STENT; VISUAL ANALOG SCALE;

IN-STENT RESTENOSIS; RISK FACTORS; STROKE; VERTEBRAL ARTERY;

AGED; ARYL HYDROCARBON HYDROXYLASES; ENDOVASCULAR PROCEDURES; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME; VASCULAR DISEASES; VERTEBRAL ARTERY;

EID: 84892529729     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12173     Document Type: Article

References (29)

1. Caplan LR, Amarenco P, Rosengart A, et al. Embolism from vertebral artery origin occlusive disease. Neurology 1992;42:1505-1512.
2. Wityk RJ, Chang HM, Rosengart A, et al. Proximal extracranial vertebral artery disease in the New England medical center posterior circulation registry. Arch Neurol 1998;55:470-478.
3. Pant S, Neupane P, Ramesh KC, et al. Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity. Cardiology 2011;18:712-717.
4. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-1058.
5. Narasimhan S, Krim NR, Silverman G, et al. Simultaneous very late stent thrombosis in multiple coronary arteries. Tex Heart Inst J 2012;39:630-634.
6. Park JS, Kim YJ, Shin DG, et al. Clinical and angiographic outcome of sirolimus-eluting stent for the treatment of very long lesions. Korean Circ J 2006;36:490-494.
7. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005;45:1157-1164.
8. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003;35:99-106.
9. Huang J, Degnan AJ, Liu Q, et al. Comparison of NASCET and WASID criteria for the measurement of intracranial stenosis using digital subtraction and computed tomography angiography of the middle cerebral artery. J Neuroradiol 2012;39:342-345.
10. Jia DM, Chen ZB, Zhang MJ, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke 2013;44:1717-1719.
11. Kocak B, Korkmazer B, Islak C, et al. Endovascular treatment of extracranial vertebral artery stenosis. World J Radiol 2012;4:391-400.
12. Coward LJ, McCabe DJ, Ederle J, et al. Long-term outcome after angioplasty and stenting for symptomatic vertebral artery stenosis compared with medical treatment in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial. Stroke 2007;38:1526-1530.
13. Cohen DJ, Doucet M, Cutlip DE, et al. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox? Circulation 2001;104:773-778.
14. Mehilli J, Kastrati A, Bollwein H, et al. Gender and restenosis after coronary artery stenting. Eur Heart J 2003;24:1523-1530.
15. Jukema JW, Verschuren JJ, Ahmed TA, et al. Restenosis after PCI. part 1: pathophysiology and risk factors. Nat Rev Cardiol 2012;9:53-62.
16. Wasser K, Schnaudigel S, Wohlfahrt J, et al. Clinical impact and predictors of carotid artery in-stent restenosis. J Neurol 2012;259:1896-1902.
17. Burchfiel CM, Laws A, Benfante R, et al. Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation 1995;92:1430-1436.
18. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. J Am Col Cardiol 2011;4:403-410.
19. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-2560.
20. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-207.
21. Kubica A, Kozinski M, Grzesk G, et al. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 2011;32:459-466.
22. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-2436.
23. Cayla G, Hulot JS, O'Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. J Am Med Assoc 2011;306:1765-1774.
24. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009;30:1744-1752.
25. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010;303:754-762.
26. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Col Cardiol 2009;53:849-856.
27. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Col Cardiol 2010;56:134-143.
28. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
29. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Col Cardiol 2010;55:2427-2434.